Vilazodone: A novel antidepressant.
Purpose. The pharmacology and pharmacokinetics of the antidepressant vilazodone (approved for U.S. marketing in 2011) are reviewed, with an emphasis on efficacy and safety data from Phase III clinical trials. Summary. Vilazodone (marketed as Viibryd by Forest Pharmaceuticals) is a dualacting seroton...
| Publicado en: | American Journal of Health-System Pharmacy Vol. 69; no. 18; pp. 1551 - 1558 |
|---|---|
| Autores principales: | , , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Oxford University Press / USA
9/15/2012
|
| Acceso en línea: | Ver este registro en EBSCOhost |